我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

派能达胶囊对慢乙肝肝硬化患者HBeAg阴转率及IL-2水平的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2015年04期
页码:
64-66
栏目:
临床研究
出版日期:
2015-07-25

文章信息/Info

Title:
The Effect of Painengda on the Negative Rate of HBeAg and IL-2 Level of Patients withChronic Hepatitis B and Liver Fibrosis
作者:
叶蕾高瑞兰余亚平
浙江中医药大学附属第一医院,浙江 杭州 310006
Author(s):
YE Lei GAO Ruilan△ YU Yaping
Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou 310006, China
关键词:
派能达 慢性乙型病毒性肝炎 肝硬化 HBeAg IL-2
Keywords:
Painengda Hepatitis B chronic liver fibrosis HBeAg IL-2
分类号:
R256.4
DOI:
-
文献标识码:
A
摘要:
目的通过观察派能达胶囊对慢乙肝肝硬化患者HBeAg阴转率及IL-2水平的影响探讨其是否可增强抗病毒治疗疗效,为临床慢乙肝肝硬化的治疗提供帮助。方法对照组用抗病毒药(拉米夫定100mg/d+阿德福韦酯10mg/d),治疗组加用派能达胶囊(2粒/次,2次/d);派能达胶囊治疗6个月,治疗结束后所有患者继续服用抗病毒药物并随访9个月。乙肝三系每3月检测1次;治疗前及治疗结束时检测IL-2水平。结果经派能达胶囊治疗的患者治疗结束后的第6个月及第9个月,HBeAg阴转率高于对照组(P<0.05);治疗后治疗组IL-2水平高于对照组(P<0.05);治疗后治疗组IL-2水平较治疗前显著升高(P<0.05)。结论派能达胶囊可与西药联合应用于慢乙肝肝硬化患者,提高HBeAg阴转率,提高抗病毒疗效,为今后治疗慢乙肝及乙肝肝硬化提供安全有效的新方案。
Abstract:
Objective To observe the effect of Painengda on the negative rate of HBeAg and IL-2 level of patients with Chronic Hepatitis B and Liver fibrosis, investigate whether it can improve the curative effect of anti hepatitis B virus, and supply help in treatment of patients with Chronic Hepatitis B and Liver fibrosis. Methods The selected 60 patients were randomly assigned to twoGroups(30 patients in each group), the control group were treated by nucleoside analogues(Lamivudine 100mg and Adefovir 10mg once a day) while the treated group were treated by nucleoside analogues(the same as the control group) and Painengda, which dose was 2 pills twice a day. After 6 months, the treatment of Painengda was stopped, the treatment of nucleoside analogues going on in both of the groups and followed up for 9 months. In the study, every 3 months the detection of hepatitis B three was done; IL-2 levels were detected before and after treatmet. Results In the sixth and ninth month after the treatment of Painengda, the negative rate of HBeAg in the treated group was higher than that in the control group(P<0. 05); The IL-2 level was higher in the treated group than that in the control group, too(P<0. 05);In the treated group itself , IL-2 level was enhanced after treatment (P<0. 05). Conclusion Painengda combined with western medicine can improve the negative rate of HBeAg and improve the curative effect of anti hepatitis B virus, which helps more in treatment of patients with Chronic Hepatitis B and Liver fibrosis.

参考文献/References

[1] 徐克成,危北海,姚希贤,等. 慢性乙型肝炎当代中西医结合治疗[J]. 中国中西医结合脾胃病杂志,2000,8(1):3-6.
[2] 中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 肝脏,2005,10(4):348-357.
[3] 任应秋. 中医各家学说[M]. 上海:上海科学技术出版社,1980:30.
[4] 苏和平. 中医对乙型病毒性肝炎病因病机特性的初探[J]. 陕西中医,2001,22(1):27-28.
[5] 王福生,张政. 宿主免疫状态决定慢性乙肝的转归和临床疗效[C]//第6届全国免疫学术大会论文集,2008:38-40.
[6] 马逢顺,高瑞兰,林筱洁,等. 升血灵胶囊(人参总皂苷)治疗免疫性血小板减少症的临床研究[J]. 浙江中医药大学学报,2012,36(2):137-140.
[7] 叶宝东,孙成龙,林胜云,等. 升血灵联合环孢霉素A治疗重型再生障碍性贫血临床观察[J]. 世界中西医结合杂志,2010,5(2):133-136.
[8] 魏守超,杜爱萍. 升血灵冲剂治疗肿瘤患者化疗所致骨髓抑制40例[J]. 中国民间疗法,2003,11(5):57-58.
[9] 周郁鸿,郭宇,胡致平,等. 升血灵胶囊联合ALG/ATG和CSA治疗重型再生障碍性贫血疗效的临床观察[J]. 浙江中医药大学学报,2009,33(2):175-177.
[10] SHAO Keding, ZHOU Yuhong, SHEN Yiping, et al. Treatment of 37 patients with refractory idiopathic thrombocytopenic purpura by Shengxueling(SXL)[J]. Chin J Integr Med,2001,13(1):33-36.
[11] 何生松,李淑莉,熊莉娟,等. IFN-α治疗慢性乙肝抗病毒疗效与细胞因子变化关系分析[J]. 中国病毒学,2000,15(4):342-345.
[12] 茅益民,曾民德. 抗乙型病毒性肝炎新药-阿德福韦酯[J]. 中华肝脏病杂志,2004,12(1):61-63.
[13] 辛永宁,宣世英,孙樱. 慢性乙型肝炎Th1/Th2细胞的免疫功能研究进展[J]. 临床肝胆病杂志,2005,21(3):182-184.
[14] Ariyasu T, TanakaT, FujiokaN, et al. Effects of interferon-alpha sub-types on the TH1 /TH2 balance in peripheral blood mononuclear cells from patientswith hepatitis virus infection-associated liver disorders[J]. In Vitro CellDev-Biol-Anim,2005,41(1-2):50-56.
[15] 郭秀荣,宋立新,周智宏,等. 乙肝疫苗与白介素-2联合免疫对 HBsAb 产生的影响[J]. 预防医学情报杂志,2014,30(12):995-997.
[16] 顾华爱,汪月祥,李丽敏. 慢性乙型病毒性肝炎患者血清细胞因子与超敏C反应蛋白水平分析[J]. Chinese General Pratice,2011,14(7C):2431-2432.

备注/Memo

备注/Memo:
* 基金项目: 2012年浙江省中医药科学研究基金计划项目(2012ZA041) 收稿日期: 2015 - 05 - 12 作者简介: 叶蕾(1968-),女,浙江湖州人,副主任医师,研究方向:中西医结合肝病研究。△通信作者:高瑞兰,E-mail:gaoruilan@126.com
更新日期/Last Update: 2015-07-30